H
Helena Barrasa
Publications - 13
Citations - 454
Helena Barrasa is an academic researcher. The author has contributed to research in topics: Population & Pharmacodynamics. The author has an hindex of 6, co-authored 11 publications receiving 269 citations.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria.
Helena Barrasa,Jordi Rello,Sofia Tejada,Alejandro Martín,Goiatz Balziskueta,Cristina Vinuesa,Borja Fernández-Miret,Ana Villagrá,Ana Vallejo,Ana San Sebastián,Sara Cabañes,Sebastián Iribarren,Fernando Fonseca,Javier Maynar +13 more
TL;DR: This early experience with SARS-CoV-2 in Spain suggests that a strategy of right oxygenation avoiding non-invasive mechanical ventilation was life-saving.
Journal ArticleDOI
Augmented Renal Clearance in Critically Ill Patients: A Systematic Review
Idoia Bilbao-Meseguer,Alicia Rodríguez-Gascón,Helena Barrasa,Arantxazu Isla,María Ángeles Solinís +4 more
TL;DR: Augmented renal clearance is a prevalent condition in critically ill patients, especially in young people, with urinary CrCl being the best diagnostic method because mathematical estimates tend to underestimate CrCl.
Journal ArticleDOI
Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective.
Helena Barrasa,Amaia Soraluce,Elena Usón,Javier Sainz,Alejandro Martín,José Ángel Sánchez-Izquierdo,Javier Maynar,Alicia Rodríguez-Gascón,Arantxazu Isla +8 more
TL;DR: ARC increases linezolid CL and leads to a high risk of underexposure with the standard dose, but an infusion rate of 75 mg/h should be considered to ensure C ≥2 2mg/mL, while continuous infusion increases the PTA.
Journal ArticleDOI
Population pharmacokinetics of daptomycin in critically ill patients.
Amaia Soraluce,Eduardo Asín-Prieto,Alicia Rodríguez-Gascón,Helena Barrasa,Javier Maynar,E. Carcelero,D. Soy,Arantxazu Isla +7 more
TL;DR: The PK/PD analysis confirmed that 280- and 420-mg/d dosages would not be enough to achieve high probabilities of target attainment for MIC values ≥ 1 mg/L in patients with Clcr ≥ 60 mL/min or in subjects with lower Clcrs but receiving CRRT.
Journal ArticleDOI
Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment
Helena Barrasa,Amaia Soraluce,Arantxazu Isla,Alejandro Martín,Javier Maynar,Andrés Canut,José Ángel Sánchez-Izquierdo,Alicia Rodríguez-Gascón +7 more
TL;DR: The standard dose (600mg q12h) ensures a moderately high probability of treatment success in anuric patients when the infection is due to microorganisms with MIC≤2mg/L; in patients with residual renal function, the standard dose is insufficient, but 900mg q8h provide higher probability of Treatment success without compromising the safety.